MedTrace Logo

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

NCT05481437 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Brentuximab Vedotin especially myelosupression, peripheral neuropathy, and lung disorder.

During the study, pediatric participants with HL will take Brentuximab Vedotin injection and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine) according to their clinic's standard practice. The study doctors will check for side effects from Brentuximab Vedotin for 26 weeks.

Conditions

Interventions

DRUG

Brentuximab Vedotin

Brentuximab Vedotin injection, 50 mg, once every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481437 on ClinicalTrials.gov